【摘要】 为了解自身免疫性甲状腺疾病患者体内刺激型及阻断型抗体共存情况，检测了４２７例Ｇｒａｖｅｓ病（Ｇｒａｖｅｓ′ｄｉｓｅａｓｅ，ＧＤ）及１０６例桥本甲状腺炎（Ｈａｓｈｉｍｏｔｏ′ｓｔｈｙｒｏｄｉｔｉｓ，ＨＴ）患者血中甲状腺刺激抗体（ＴＳＡｂ）及甲状腺刺激阻断抗体（ＴＳＢＡｂ）。结果：ＧＤ组及ＨＴ组ＴＳＡｂ、ＴＳＢＡｂ的阳性率分别为９１．６％、７．７％及１４．２％、３７．７％。ＧＤ患者ＴＳＡｂ及ＴＳＢＡｂ均呈阳性者１８例，ＨＴ者两抗体共存的病人为１２例。其中，１４例ＧＤ患者有３例于１～３年内转化为甲减，１例ＨＴ者发展为甲亢，随病变性质的改变，患者血中ＴＳＡｂ及ＴＳＢＡｂ活性亦呈现相应的变化。提示两类抗体活性的消长是甲状腺功能转化的重要原因。更多还原

【Abstract】 Thyroid stimulating antibody(TSAb) and thyroid stimulation blocking antibody(TSBAb) were measured using cell culture bioassay in patients with Graves′ disease (GD) and Hashimoto′s thyroiditis(HT). The results showed that∶(1) The positive rate of TSAb and TSBAb in patients with GD or HT were 91.6% and 7.7% or 14.2% and 37.7%. (2)Both TSAb and TSBAb were detected in 18 out of 427 patients with GD and 12 of 106 cases with HT. (3)14 patients with GD and 5 with HT presenting both antibodies were followed up. After 1￣3 years 3 GD cases experienced primary hypothyroidism, 1 HT patient became thyrotoxic. All the four patients had corresponding alteration of TSAb and TSBAb activities. The finding suggests that both thyroid stimulating and blocking antibodies can coexist in one patient with autoimmune thyroid disease, and the thyroid function in such patients may change depending upon the alteration in balance between these two types of antibody.更多还原